Xanthotoxol (XT) - a potent 5-HT antagonist
Sethi, O.P.; Naik, K.
Indian Journal of Physiology and Pharmacology 23(2): 142-143
1979
ISSN/ISBN: 0019-5499 PMID: 489098 Document Number: 148600
Document emailed within 1 workday
Related Documents
Wirth, K.J.; Wiemer, G.; Schölkens, B.A. 1992: DesArg10[Hoe 140] is a potent B1 bradykinin antagonist Agents and Actions. Supplements 38: 406-413Debeljuk, L.; Schally, A.V. 1986: Antifertility effects of a potent LH-RH antagonist in male and female rats International Journal of Fertility 31(4): 284-292
Ligneau, X.; Lin, J.; Vanni-Mercier, G.; Jouvet, M.; Muir, J.L.; Ganellin, C.R.; Stark, H.; Elz, S.; Schunack, W.; Schwartz, J. 1998: Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist Journal of Pharmacology and Experimental Therapeutics 287(2): 658-666
Bellemann, P.; Ferry, D.; Lübbecke, F.; Glossman, H. 1981: 3H]-Nitrendipine, a potent calcium antagonist, binds with high affinity to cardiac membranes Arzneimittel-Forschung 31(12): 2064-2067
Pendley, C.E.; Fitzpatrick, L.R.; Capolino, A.J.; Davis, M.A.; Esterline, N.J.; Jakubowska, A.; Bertrand, P.; Guyon, C.; Dubroeucq, M.C.; Martin, G.E. 1995: RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat Journal of Pharmacology and Experimental Therapeutics 273(3): 1015-1022
Cutler, G.B.; Sauer, M.A.; Loriaux, D.L. 1979: SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone Journal of Pharmacology and Experimental Therapeutics 209(1): 144-146
Wilkinson, A.; Courtney, M.; Westlind-Danielsson, A.; Hallnemo, G.; Akerman, K.E. 1994: Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow Journal of Pharmacology and Experimental Therapeutics 271(3): 1314-1319
Katz, L.B.; Scott, C.K.; Shriver, D.A. 1986: Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine Journal of Pharmacology and Experimental Therapeutics 238(2): 587-593
Kadowaki, M.; Nagakura, Y.; Tomoi, M.; Mori, J.; Kohsaka, M. 1993: Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo Journal of Pharmacology and Experimental Therapeutics 266(1): 74-80
Adkison, K.K.; Halm, K.A.; Shaffer, J.E.; Drewry, D.; Sinhababu, A.K.; Berman, J. 1998: Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parameters Pharmaceutical Biotechnology 11: 423-443
Martin, P.L.; Wysocki, R.J.; Barrett, R.J.; May, J.M.; Linden, J. 1996: Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors Journal of Pharmacology and Experimental Therapeutics 276(2): 490-499
Bonacchi, G.; Agostini, O.; Fedi, M.; Bacciarelli, C.; Boni, P.; Castellucci, A.; Perretti, F.; Manzini, S. 1988: Resolution and pharmacological properties of the enantiomers of the potent alpha-adrenoceptor antagonist 1-[2-ethoxy-2-(3'-pyridyl)ethyl]-4-(2'-methoxy-phenyl)piperazine Arzneimittel-Forschung 38(5): 650-654
Cohen, M.L.; Robertson, D.W.; Bloomquist, W.E.; Wilson, H.C. 1992: LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis Journal of Pharmacology and Experimental Therapeutics 261(1): 202-208
Belardinelli, L.; Shryock, J.C.; Zhang, Y.; Scammells, P.J.; Olsson, R.; Dennis, D.; Milner, P.; Pfister, J.; Baker, S.P. 1995: 1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells Journal of Pharmacology and Experimental Therapeutics 275(3): 1167-1176
Takemoto, Y.; Yuki, H.; Nishida, A.; Ito, H.; Kobayashi-Uchida, A.; Takinami, Y.; Akuzawa, S.; Ohta, M.; Satoh, M.; Semple, G.; Miyata, K. 1998: Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula Arzneimittel-Forschung 48(4): 403-407
Rodríguez de Fonseca, F.; Rubio, P.; Menzaghi, F.; Merlo-Pich, E.; Rivier, J.; Koob, G.F.; Navarro, M. 1996: Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats Journal of Pharmacology and Experimental Therapeutics 276(1): 56-64
Sekiguchi, H.; Hamada, K.; Taga, F.; Nishino, K. 1993: Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats Arzneimittel-Forschung 43(2): 134-138
Abou Elzahab, M. 1993: Photooxygenation of some potentially skin-photosensitizing hydroxyfurocoumarins. Part 2: Xanthotoxol and bergaptol Die Pharmazie 48(2): 144-145
Ennis, C.; Cox, B. 1980: The dopamine receptor antagonist domperidone is also a competitive antagonist at alpha 1-adrenoceptors Journal of Pharmacy and Pharmacology 32(6): 434-435
Gabay, C.; Porter, B.; Fantuzzi, G.; Arend, W.P. 1998: Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo Journal of Immunology 159(12): 5905-5913